Literature DB >> 11067962

Progression from acute to chronic disease in a murine parent-into-F1 model of graft-versus-host disease.

J R Tschetter1, E Mozes, G M Shearer.   

Abstract

The parent-into-immunocompetent-F(1) model of graft-vs-host disease (GVHD) induces immune dysregulation, resulting in acute or chronic GVHD. The disease outcome is thought to be determined by the number of parental anti-F(1) CTL precursor cells present in the inoculum. Injection of C57BL/6 (B6) splenocytes into (B6 x DBA/2)F(1) (B6D2F(1)) mice (acute model) leads to extensive parental cell engraftment and early death, whereas injection of DBA/2 cells (chronic model) results in little parental cell engraftment and a lupus-like disease. This study demonstrated that injection of BALB/c splenocytes into (BALB/c x B6)F(1) (CB6F(1)) mice resulted in little engraftment of parental lymphocytes and the development of lupus as expected. Injection of B6 splenocytes into CB6F(1) initiated an initial burst of parental cell engraftment similar to that of B6 into B6D2F(1). However, the acute disease resolved, and the CB6F(1) mice went on to develop chronic GVHD with detectable Abs to ssDNA, dsDNA, and extractable nuclear Ags. Limiting dilution CTL assays determined that B6 splenocytes have CTL precursor frequencies of 1/1000 against both CB6F(1) and B6D2F(1), whereas DBA/2 and BALB/c splenocytes have a CTL precursor frequency of 1/20,000 for their respective F(1)s. The Th cell precursor frequency for B6 anti-DBA/2 was 3-fold higher than that for B6 anti-BALB/c determined by limiting dilution proliferation assays. These results indicate the importance of adequate allospecific helper as well as effector T cells for the induction and maintenance of acute GVHD in this model, and presents an unexpected model in which initial acute GVHD is replaced by the chronic form of disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11067962     DOI: 10.4049/jimmunol.165.10.5987

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Immunotherapeutic targeting of LIGHT/LTβR/HVEM pathway fully recapitulates the reduced cytotoxic phenotype of LIGHT-deficient T cells.

Authors:  Maria-Luisa del Rio; Carlos Fernandez-Renedo; Olivier Chaloin; Stefanie Scheu; Klaus Pfeffer; Yasushi Shintani; Jose-Antonio Perez-Simon; Pascal Schneider; Jose-Ignacio Rodriguez-Barbosa
Journal:  MAbs       Date:  2016-01-11       Impact factor: 5.857

Review 2.  Implications of the parent-into-F1 model for human lupus pathogenesis: roles for cytotoxic T lymphocytes and viral pathogens.

Authors:  Charles S Via
Journal:  Curr Opin Rheumatol       Date:  2010-09       Impact factor: 5.006

Review 3.  Advances in lupus stemming from the parent-into-F1 model.

Authors:  Charles S Via
Journal:  Trends Immunol       Date:  2010-03-31       Impact factor: 16.687

4.  Pre-clinical screening of immunomodulatory compounds using the parent-into-F1 model.

Authors:  Charles S Via
Journal:  Clin Immunol       Date:  2011-06-12       Impact factor: 3.969

5.  Defective in vitro IL-2 production in lupus is an early but secondary event paralleling disease activity: evidence from the murine parent-into-F1 model supports staging of IL-2 defects in human lupus.

Authors:  Charles S Via; Gene M Shearer
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

6.  CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.

Authors:  Roman Puliaev; Irina Puliaeva; Lisbeth A Welniak; Abigail E Ryan; Mark Haas; William J Murphy; Charles S Via
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

Review 7.  Murine models of chronic graft-versus-host disease: insights and unresolved issues.

Authors:  Yu-Waye Chu; Ronald E Gress
Journal:  Biol Blood Marrow Transplant       Date:  2008-02-13       Impact factor: 5.742

Review 8.  Mouse models of bone marrow transplantation.

Authors:  Pavan Reddy; Robert Negrin; Geoffrey R Hill
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

9.  The Parent-into-F1 Model of Graft-vs-Host Disease as a Model of In Vivo T Cell Function and Immunomodulation.

Authors:  R A Puliaev; I A Puliaeva; A E Ryan; C S Via
Journal:  Curr Med Chem Immunol Endocr Metab Agents       Date:  2005-12-01

10.  Allogeneic non-adherent bone marrow cells facilitate hematopoietic recovery but do not lead to allogeneic engraftment.

Authors:  Stephan Fricke; Manuela Ackermann; Alexandra Stolzing; Christoph Schimmelpfennig; Nadja Hilger; Jutta Jahns; Guido Hildebrandt; Frank Emmrich; Peter Ruschpler; Claudia Pösel; Manja Kamprad; Ulrich Sack
Journal:  PLoS One       Date:  2009-07-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.